A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3K? Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Incyte Corporation
Start Date
April 1, 2021
End Date
February 27, 2024
Administered By
Duke Cancer Institute
Awarded By
Incyte Corporation
Start Date
April 1, 2021
End Date
February 27, 2024